IGC Pharma (IGC) Asset Writedowns and Impairment (2014 - 2025)
IGC Pharma (IGC) reported Asset Writedowns and Impairment of $152000.0 for Q1 2025, up 104.66% year-over-year from $74271.2 in Q1 2024, and up 104.66% quarter-over-quarter from -$3.3 million in Q1 2024.
IGC Pharma (IGC) Asset Writedowns and Impairment (2014 - 2025) Analysis & Trends
IGC Pharma (IGC) has 12 years of Asset Writedowns and Impairment data on file, last reported at $152000.0 in Q1 2025.
- Asset Writedowns and Impairment for Q1 2025 came in at $152000.0, up 104.66% year-over-year; the trailing twelve-month figure through Mar 2025 was -$3.0 million (up 4.84% YoY), and the FY2025 annual result was $152000.0, up 63.44% from the prior year.
- Asset Writedowns and Impairment climbed to $152000.0 in Q1 2025 per IGC's latest filing, from -$3.3 million in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $152000.0 in Q1 2025 and troughed at -$3.3 million in Q1 2024.
- A 5-year average of -$587600.0 and a median of $37000.0 in 2021 frame the typical range for Asset Writedowns and Impairment.
- The sharpest annual moves came in 2023 and 2024: Asset Writedowns and Impairment soared 950.0% in 2023, then sank 2691.27% in 2024.
- A 5-year view of Asset Writedowns and Impairment shows it stood at $37000.0 in 2021, then slumped by 67.57% to $12000.0 in 2022, then soared by 950.0% to $126000.0 in 2023, then slumped by 2691.27% to -$3.3 million in 2024, then surged by 104.66% to $152000.0 in 2025.
- Business Quant data shows IGC's Asset Writedowns and Impairment at $152000.0 in Q1 2025, -$3.3 million in Q1 2024, and $126000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | IGC Pharma | 29.33 Mn | 29.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 152,000.00 |
| Mar 31, 2025 | 152,000.00 |
| Mar 31, 2024 | -3.27 Mn |
| Mar 31, 2024 | -3.27 Mn |
| Mar 31, 2023 | 126,000.00 |
| Mar 31, 2023 | 126,000.00 |
| Mar 31, 2022 | 12,000.00 |
| Mar 31, 2022 | 12,000.00 |
| Jun 30, 2021 | 37,000.00 |
| Jun 30, 2021 | 37,000.00 |
| Mar 31, 2020 | 782,000.00 |
| Mar 31, 2020 | 782,000.00 |
| Mar 31, 2019 | -47,000.00 |
| Mar 31, 2019 | -47,000.00 |
| Dec 31, 2018 | 650,000.00 |
| Dec 31, 2018 | 650,000.00 |
| Mar 31, 2017 | 6,980.00 |
| Mar 31, 2017 | 6,980.00 |
| Dec 31, 2016 | -4,910.00 |
| Dec 31, 2016 | -4,910.00 |